Frontlight ResearchEarly access
Taking peoplePhase 2
Riluzole in spinocerebellar ataxia type 7
Key facts
- Who runs it
- Universita Degli Studi Di Roma La Sapienza
- Where
- Italy4 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 24 people, planned
- Started
- 7 Dec 2021
- Planned end
- 11 Aug 2025
- Type of study
- Interventional
- Record updated
- 27 October 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male and female of any race and > 6 years old
- Positive genetic test for SCA7
- Signed Informed Consent (in case of minors, written informed consent must be obtained by parents or legal representative)
Who cannot take part
- Female subjects: pregnant or lactating women cannot participate in the study. Women of childbearing potential cannot participate unless willing to use highly effective contraception methods as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence. In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study drug. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation. Such conditions may include cardiovascular, pulmonary, hepatic, renal, severe systemic mycotic infections, metabolic diseases or malignancies
- Any medical or psychiatric condition that may affect the subject ability to give informed consent, or to complete the study, or if the subject is considered by the treating neurologist to be, for any other reason, an unsuitable candidate for this study
- Known hypersensitivity to any component of riluzole (Glentek)
- Hepatic diseases with serum values of alanine aminotransferase, aspartate aminotransferase or bilirubin > 1·5 times above normal limit
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the two study arms for the proportion of patients who remain stable at SARA score and visual acuity at 18 months respect to run-in.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, doubleblind, placebo-controlled pilot trial with a lead in phase
- Record updated
- 27 October 2025